Tacalyx
PrivateLast Round
Seed
Apr 29, 2026
Total Funding Raised
$26.91M
Momentum Score
25 /100
Company Overview
Tacalyx is a biotechnology company that develops novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tacalyx Comps
Public and private peers based on sector, stage, and business model.
Tacalyx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Apr 29, 2026 | ||||
| Seed | Jun 11, 2024 | ||||
| Seed | Sep 25, 2019 |
Key People
Founding team and executive leadership
Tacalyx Investors
Notable investors and investment history
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 29, 2026
$12M round with participation from Eurazeo and Boehringer Ingelheim.
- Feb 16, 2026
Grew 23% QoQ from 13 to 16 employees.
Tacalyx Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Tacalyx's valuation, stock price, and market status.
